MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director Stanley C. Erck sold 21,607 shares of the business's stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the sale, the director now directly owns 269,118 shares in the company, valued at approximately $998,427.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
MaxCyte Stock Up 1.1 %
Shares of MXCT opened at $3.74 on Thursday. The stock has a market cap of $392.04 million, a PE ratio of -10.69 and a beta of 1.40. MaxCyte, Inc. has a 12-month low of $2.45 and a 12-month high of $5.55. The business has a 50-day simple moving average of $4.16 and a two-hundred day simple moving average of $4.26.
MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. MaxCyte had a negative net margin of 77.97% and a negative return on equity of 15.52%. The business had revenue of $10.43 million during the quarter, compared to analyst estimates of $8.20 million. During the same quarter last year, the business earned ($0.10) EPS. On average, equities research analysts expect that MaxCyte, Inc. will post -0.44 EPS for the current year.
Hedge Funds Weigh In On MaxCyte
War on Elon Escalates…
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
Hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. acquired a new stake in MaxCyte in the first quarter valued at $28,000. PNC Financial Services Group Inc. bought a new stake in shares of MaxCyte in the 4th quarter valued at about $29,000. China Universal Asset Management Co. Ltd. increased its stake in shares of MaxCyte by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company's stock valued at $83,000 after buying an additional 7,898 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of MaxCyte by 20.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company's stock worth $106,000 after acquiring an additional 4,320 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of MaxCyte by 22.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company's stock worth $128,000 after acquiring an additional 5,927 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company's stock.
MaxCyte Company Profile
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
